Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand

Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.

Published on RocksNews

29 Oct 2026, 11:09 UTC

Updated

29 Oct 2026, 11:09 UTC

Language

English